Pricing Log in Create free account

Alnylam Pharmaceuticals, Inc. (ALNY) vs Royalty Pharma PLC (RPRX)

Alnylam Pharmaceuticals, Inc. and Royalty Pharma PLC are both Biotechnology companies. Alnylam Pharmaceuticals, Inc. and Royalty Pharma PLC are of similar size ($34.3B and $31.3B). Alnylam Pharmaceuticals, Inc. trades at the lower P/E: 39.5× against 42.3×. Alnylam Pharmaceuticals, Inc. grew revenue faster over the last twelve months: 95.1% against 10.0%. Royalty Pharma PLC has the higher net margin (32.0% vs 16.1%) and the higher return on invested capital (5.28% vs 0.00%). Across the 22 metrics below, Alnylam Pharmaceuticals, Inc. leads on 13 and Royalty Pharma PLC on 9.

Valuation

Metric ALNY RPRX Biotechnology median
P/E 39.50 42.27 8.50
P/S 6.45 10.76 9.71
P/B 22.87 2.79 2.13
Price to free cash flow 37.78 20.82 20.82
EV/EBITDA 27.19 22.88 0.64
EV/Sales 5.97 13.96 9.21
Earnings yield 2.53% 2.37% (33.15%)
Free cash flow yield 2.65% 4.80% (25.50%)

Profitability

Metric ALNY RPRX Biotechnology median
Gross margin 79.65% 100.00% 65.16%
Operating margin 20.81% 59.61% 0.00%
Net margin 16.13% 32.02% 0.00%
Free cash flow margin 17.07% 51.66% 0.00%
Return on equity 96.55% 8.42% (56.36%)
Return on assets 15.30% 4.26% (48.04%)
Return on invested capital 0.00% 5.28% 0.00%

Growth

Metric ALNY RPRX Biotechnology median
Revenue growth (TTM) 95.14% 10.01% 6.02%
EPS growth (last fiscal year) 206.88% (5.52%) 30.26%
Revenue growth, 5-year CAGR 49.77% 2.30% 9.41%
Net income growth, 5-year CAGR 0.00% (4.59%) 0.00%

Health

Metric ALNY RPRX Biotechnology median
Debt to equity 0.75 0.92 0.00
Current ratio 3.05 2.80 4.72
Net debt to EBITDA (3.41) 5.22 0.96

Dividend

Metric ALNY RPRX Biotechnology median
Dividend yield — 1.51% 0.09%
Payout ratio — 0.64 —

Size

Metric ALNY RPRX Biotechnology median
Market cap 31.32b 34.28b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack